AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 300 mg
Number of subjects: 40
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 600 mg
Number of subjects: 40
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 900 mg
Number of subjects: 40
Study 2044652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 150 mg
Number of subjects: 40
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 300-900 mg
Number of subjects: 40
Study 2044652 — intervention group
Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol)
Number of subjects: 40
Study 6365147 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA and etretinate (0.75 mg/kg)
Number of subjects: 28
Study 6365147 — intervention group
Group type: COMPARATOR
Intervention: PUVA and placebo
Number of subjects: 28
Study 31353759 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 36
Study 30533438 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with ropivacaine
Number of subjects: 213
Study 30533438 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with levobupivacaine
Number of subjects: 213
Study 30533438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PCEA)
Number of subjects: 213
Study 26976426 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg once per day
Number of subjects: 75
Study 26976426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg with pictilisib 260 mg once per day
Number of subjects: 75
Study 25244631 — intervention group
Group type: EXPERIMENTAL
Intervention: 5/0 gauge polyglactin 910 sutures
Number of subjects: 42
Study 25244631 — intervention group
Group type: EXPERIMENTAL
Intervention: 7/0 gauge polyglactin 910 sutures
Number of subjects: 42
Study 24105720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after autologous transplantation
Number of subjects: 1159
Study 21926153 — intervention group
Group type: EXPERIMENTAL
Intervention: treatment to target (TT)
Number of subjects: 493
Study 21926153 — intervention group
Group type: COMPARATOR
Intervention: treatment as needed (PRN)
Number of subjects: 493
Study 18760765 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Number of subjects: 188
Study 18760765 — intervention group
Group type: COMPARATOR
Intervention: Fellow control eyes
Number of subjects: 188
Study 17111793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical and systemic antibiotics
Number of subjects: 6922
Study 17111793 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobials alone (or topical plus systemic versus systemic alone)
Number of subjects: 6922
Study 17111793 — intervention group
Group type: COMPARATOR
Intervention: Control group (combination of topical and systemic antibiotics)
Number of subjects: 6922
Study 17111793 — intervention group
Group type: COMPARATOR
Intervention: Control group (topical antimicrobials alone)
Number of subjects: 6922
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised QUICKI at 40 mU/m(2).min (n = 30)
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI-glycerol at 40 mU/m(2).min (n = 30)
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI at 40 mU/m(2).min (n = 30)
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: Log HOMA at 40 mU/m(2).min (n = 30)
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: All indexes at 75 mU/m(2).min (n = 118)
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised QUICKI and QUICKI-glycerol in lean control subjects at 40 mU/m(2).min
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised QUICKI and QUICKI-glycerol in impaired glucose tolerance subjects
Number of subjects: 148
Study 14557474 — intervention group
Group type: EXPERIMENTAL
Intervention: QUICKI and revised QUICKI
Number of subjects: 148
Study 10814631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (2 mg/kg intranasally)
Number of subjects: 14
Study 10814631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9121824 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Helpfulness Questionnaire (THQ)
Number of subjects: 0
Study 1797464 — intervention group
Group type: EXPERIMENTAL
Intervention: Norinyl 1+35 (35 mcg ethinyl estradiol)
Number of subjects: 1698
Study 1797464 — intervention group
Group type: COMPARATOR
Intervention: Norinyl 1+50 (50 mcg mestranol)
Number of subjects: 1698
Study 1797464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1698
Study 6356005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol (10 mg/kg body weight, daily 12-hour treatments over 5 days)
Number of subjects: 26
Study 6356005 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol (control)
Number of subjects: 26
Study 31119456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐meal rapid‐acting insulin
Number of subjects: 71
Study 31119456 — intervention group
Group type: COMPARATOR
Intervention: No insulin (control)
Number of subjects: 71
Study 29378662 — intervention group
Group type: EXPERIMENTAL
Intervention: ART refills supplied 3-monthly within CARGs
Number of subjects: 5760
Study 29378662 — intervention group
Group type: EXPERIMENTAL
Intervention: ART refills supplied 6-monthly within CARGs
Number of subjects: 5760
Study 29378662 — intervention group
Group type: COMPARATOR
Intervention: ART refills supplied 3-monthly from the health facility (control arm)
Number of subjects: 5760
Study 27460321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lava COS
Number of subjects: 10
Study 27460321 — intervention group
Group type: EXPERIMENTAL
Intervention: iTero
Number of subjects: 10
Study 27460321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec Bluecam
Number of subjects: 10
Study 27460321 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 10
Study 24784879 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet therapy (n=42)
Number of subjects: 84
Study 24784879 — intervention group
Group type: COMPARATOR
Intervention: Natural course (n=42)
Number of subjects: 84
Study 21739259 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22
Study 21739259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20950883 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based counselling training for nurses
Number of subjects: 584
Study 20950883 — intervention group
Group type: COMPARATOR
Intervention: Control group (nurses trained after the study)
Number of subjects: 584
Study 17659159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day added to ongoing statin therapy
Number of subjects: 5039
Study 17659159 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ongoing statin therapy
Number of subjects: 5039
Study 16338558 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 18
Study 16338558 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 18
Study 12522743 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention program based on the transtheoretical model, including written materials and teaching activities for different stages of exercise.
Number of subjects: 193
Study 12522743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 193
Study 9789893 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.2 to 2.0 mg/day for 6 to 12 months
Number of subjects: 0
Study 9789893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7706098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 30
Study 7706098 — intervention group
Group type: COMPARATOR
Intervention: 45-degree upright position
Number of subjects: 30
Study 2705633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg daily
Number of subjects: 44
Study 2705633 — intervention group
Group type: COMPARATOR
Intervention: Control (no gemfibrozil)
Number of subjects: 44
Study 701664 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized ragweed
Number of subjects: 19
Study 701664 — intervention group
Group type: COMPARATOR
Intervention: Monomeric ragweed
Number of subjects: 19
Study 701664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 30361759 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT cuff pressure adjusted to 20 mmHg after retractor placement
Number of subjects: 162
Study 30361759 — intervention group
Group type: COMPARATOR
Intervention: No adjustment of ETT cuff pressure
Number of subjects: 162
Study 27671007 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal additional high-dose oral vitamin A supplementation for 28 days (exact dosage not specified)
Number of subjects: 0
Study 27671007 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic vitamin A (1000 IU/kg/day)
Number of subjects: 0
Study 26046790 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) cystoscopy
Number of subjects: 384
Study 26046790 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI) cystoscopy
Number of subjects: 384
Study 23022464 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg HA with 300 μg aluminum phosphate (AlPO4)
Number of subjects: 60
Study 23022464 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 μg HA
Number of subjects: 60
Study 23022464 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg HA
Number of subjects: 60
Study 23022464 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 21807321 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided therapy
Number of subjects: 130
Study 21807321 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone (Control)
Number of subjects: 130
Study 19929037 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICDs)
Number of subjects: 983
Study 19929037 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDs
Number of subjects: 983
Study 16616620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning for 20 hours each day during the acute phase for a maximum of 7 days
Number of subjects: 0
Study 16616620 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 0
Study 16616620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0
Study 12745612 — intervention group
Group type: COMPARATOR
Intervention: Natural history phase
Number of subjects: 138
Study 12745612 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 138
Study 11081892 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP treatment (0.05 microg x kg(‐1) x min(‐1) for 6 hours)
Number of subjects: 18
Study 11081892 — intervention group
Group type: COMPARATOR
Intervention: No ANP treatment (control group)
Number of subjects: 18
Study 8931065 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention (weekly sessions with a nurse over 3-6 weeks using counselling, breathing re‐training, relaxation, and teaching coping strategies)
Number of subjects: 20
Study 8931065 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention
Number of subjects: 20
Study 8931065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 1406008 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 73
Study 1406008 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream
Number of subjects: 73
Study 1406008 — intervention group
Group type: COMPARATOR
Intervention: No cream (control)
Number of subjects: 73
Study 3159163 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine (20 mg once daily for three weeks)
Number of subjects: 30
Study 3159163 — intervention group
Group type: COMPARATOR
Intervention: nitrendipine (10 mg twice daily for four weeks)
Number of subjects: 30
Study 3159163 — intervention group
Group type: COMPARATOR
Intervention: captopril (25 mg twice daily for four weeks)
Number of subjects: 30
Study 3159163 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine plus nitrendipine plus captopril (same dosages for four weeks)
Number of subjects: 30
Study 30082139 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 223
Study 30082139 — intervention group
Group type: COMPARATOR
Intervention: Passive gravity drain
Number of subjects: 223
Study 27106949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy-based breast feeding educational programme (SEBEP)
Number of subjects: 0
Study 27106949 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 24787561 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous audiovisual feedback training
Number of subjects: 200
Study 24787561 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous year's participants)
Number of subjects: 200
Study 24787561 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 200
Study 24787561 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 200
Study 22396514 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized anteromesial temporal resection (AMTR) plus AED treatment (n = 15)
Number of subjects: 38
Study 22396514 — intervention group
Group type: COMPARATOR
Intervention: Continued AED treatment (n = 23)
Number of subjects: 38
Study 20498393 — intervention group
Group type: EXPERIMENTAL
Intervention: FU-based therapy (either FU + levamisole or FU + leucovorin)
Number of subjects: 457
Study 20498393 — intervention group
Group type: EXPERIMENTAL
Intervention: FU (in patients with dMMR tumors)
Number of subjects: 457
Study 20498393 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group for dMMR patients)
Number of subjects: 457
Study 20498393 — intervention group
Group type: EXPERIMENTAL
Intervention: FU-based therapy (in pooled data set)
Number of subjects: 457
Study 18356346 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood pressure measurement and written information about hypertension with advice to see a general practitioner if indicated
Number of subjects: 400
Study 18356346 — intervention group
Group type: COMPARATOR
Intervention: No measurement or advice (Control)
Number of subjects: 400
Study 15318470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 15318470 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 90
Study 15318470 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study 11228380 — intervention group
Group type: EXPERIMENTAL
Intervention: QS‐21 (50 and 100 microg)
Number of subjects: 3
Study 11228380 — intervention group
Group type: EXPERIMENTAL
Intervention: rsgp120 formulated with QS‐21
Number of subjects: 3
Study 11228380 — intervention group
Group type: COMPARATOR
Intervention: rsgp120 formulated with alum alone
Number of subjects: 3
Study 11228380 — intervention group
Group type: EXPERIMENTAL
Intervention: QS‐21 formulations
Number of subjects: 3
Study 9052304 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% (10 mL)
Number of subjects: 8
Study 9052304 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (10 mL)
Number of subjects: 8
Study 9052304 — intervention group
Group type: COMPARATOR
Intervention: Control sham (0.5 mL saline)
Number of subjects: 8
Study 8300895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual estradiol hydroxypropyl‐beta‐cyclodextrin (estradiol‐HP beta CD) 0.675 mg
Number of subjects: 5
Study 8300895 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized estradiol 1 mg
Number of subjects: 5
Study 8300895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual estradiol hydroxypropyl‐beta‐cyclodextrin (estradiol‐HP beta CD)
Number of subjects: 5
Study 8300895 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol hydroxypropyl‐beta‐cyclodextrin
Number of subjects: 5
Study 8300895 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized estradiol
Number of subjects: 5
Study 8300895 — intervention group
Group type: COMPARATOR
Intervention: Both oral doses (estradiol-HP beta CD and micronized estradiol)
Number of subjects: 5
Study 3079477 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus leucovorin (CF)
Number of subjects: 0
Study 31595772 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of benzodiazepines
Number of subjects: 10263
Study 31595772 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of benzodiazepines
Number of subjects: 10263
Study 30441880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Antioxidant Diet (LAD), with less than two servings of fruit and vegetables per day, avoiding cocoa products, coffee, and tea.
Number of subjects: 22
Study 30441880 — intervention group
Group type: COMPARATOR
Intervention: Usual Diet (UD), consuming healthy food rich in polyphenols.
Number of subjects: 22
Study 27558901 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oxycodone plus naloxone up to 20 mg per day
Number of subjects: 346
Study 27558901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 24025063 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 8
Study 24025063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22854394 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% plus 150 μg clonidine
Number of subjects: 60
Study 22854394 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.5%
Number of subjects: 60
Study 20001576 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed 100 whey formula (pHF)
Number of subjects: 15
Study 18588370 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravenous infusions of cyclophosphamide 15 mg/kg daily for two days, methylprednisolone one gram daily for three days, and mesna 15 mg/kg for four days.
Number of subjects: 45
Study 18588370 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment.
Number of subjects: 45
Study 16808365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prophylactic antibiotics
Number of subjects: 1040
Study 16808365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1040
Study 12900339 — intervention group
Group type: COMPARATOR
Intervention: TAXUS-SR
Number of subjects: 536
Study 12900339 — intervention group
Group type: COMPARATOR
Intervention: TAXUS-MR
Number of subjects: 536
Study 10634839 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 6 mg/kg
Number of subjects: 30
Study 10634839 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 30
Study 8857657 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 0
Study 8857657 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg ketamine + 0.1 mg/kg diazepam
Number of subjects: 0
Study 1349217 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g)
Number of subjects: 12
Study 1349217 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (500 mg)
Number of subjects: 12
Study 6381344 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral amrinone therapy (100 mg orally every 8 hours for 4 weeks)
Number of subjects: 18
Study 6381344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31917595 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (presence of stagnant wastewater, flies, solid waste, water-filled containers near households, distance from the river)
Number of subjects: 205
Study 30481374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg/mL ropivacaine infiltration followed by 2 mg/mL ropivacaine continuous wound infiltration (CWI) for 96 hours
Number of subjects: 85
Study 30481374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) for 96 hours
Number of subjects: 85
Study 30481374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg/mL ropivacaine infiltration followed by 2 mg/mL ropivacaine CWI
Number of subjects: 85
Study 30481374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 85
Study 30208394 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-efficiency (LE) high-efficiency particulate arrestance (HEPA)-type filtered air
Number of subjects: 40
Study 30208394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency (HE) true-HEPA filtered air
Number of subjects: 40
Study 30208394 — intervention group
Group type: COMPARATOR
Intervention: Sham filtration (unfiltered air)
Number of subjects: 40
Study 29771066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic budesonide injection
Number of subjects: 90
Study 29771066 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (control group-1)
Number of subjects: 90
Study 29771066 — intervention group
Group type: COMPARATOR
Intervention: Control group-2 (systemic therapy without intratympanic steroid injection)
Number of subjects: 90
Study 24889399 — intervention group
Group type: EXPERIMENTAL
Intervention: DLBP
Number of subjects: 60
Study 24889399 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH
Number of subjects: 60
Study 24889399 — intervention group
Group type: COMPARATOR
Intervention: CLBP
Number of subjects: 60
Study 24889399 — intervention group
Group type: COMPARATOR
Intervention: N
Number of subjects: 60
Study 21848574 — intervention group
Group type: EXPERIMENTAL
Intervention: prucalopride 2 mg once daily
Number of subjects: 120
Study 21848574 — intervention group
Group type: EXPERIMENTAL
Intervention: prucalopride 10 mg once daily
Number of subjects: 120
Study 21848574 — intervention group
Group type: COMPARATOR
Intervention: placebo with 400 mg moxifloxacin on day 1
Number of subjects: 120
Study 21848574 — intervention group
Group type: COMPARATOR
Intervention: placebo with moxifloxacin on day 15
Number of subjects: 120
Study 19472537 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep MMC (D‐MMC)
Number of subjects: 25